- Home
- JFR vs MDXG Comparison
JFR vs MDXG Comparison
Compare JFR & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFR | MDXG |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JFR | MDXG |
|---|---|---|
| Price | $7.83 | $6.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 621.7K | ★ 762.4K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $393,442,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | N/A | $2.11 |
| P/E Ratio | ★ N/A | $25.10 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $7.61 | $5.79 |
| 52 Week High | $8.82 | $10.14 |
Technical Indicators
Market Signals| Indicator | JFR | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 43.26 |
| Support Level | $7.87 | $6.62 |
| Resistance Level | $7.96 | $7.06 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 50.00 | 47.65 |
Price Performance
Historical ComparisonAbout JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.